Company intelligence / Profile preview

Windward Bio

Ownership: Private
Development stage: Phase 2

Overview

Windward Bio is advancing WIN378, a long-acting anti-TSLP monoclonal antibody with potential to be dosed every 6 months. The company is preparing to begin Phase 2 trials in severe asthma with initial clinical readouts expected in 2026. Additional trials are planned for asthma and COPD.[6]

Therapeutic areas: PulmonologyImmunology
Modalities: Monoclonal antibodiesBispecific antibodies
Industry: Biotech

Drug pipeline

1 asset

WIN378

Partnerships

Harbour BioMedKelun-Biotech

Beyond the preview

Go deeper on Windward Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Windward Bio.

Explore the full profile